ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 148

High Level of CD38 Expression in SLE CD8 T Cells Dictates Decreased Cytotoxicity

Eri Katsuyama, Abel Suarez-Fueyo, Sean Bradley, Michihito Kono, Lama Mulki, Vasileios C. Kyttaris and George C Tsokos, Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: CD8 cells, T cells and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: CD38 is an ectonucleotidase that has the ability to degrade nicotinamide adenine dinucleotide (NAD). The percentage of CD38 expressing CD8 T cells are increased in patients with SLE in whom cytotoxic responses are known to be decreased. We sought to determine whether CD38 is responsible for the decreased cytotoxicity in T cells from patients with SLE.

Methods:

We used sorted human primary CD8 T cells, TALL-104 and CRISPR-generated CD38 knock out Jurkat cells. Electroporation was performed using Amaxa. Cells were stimulated with anti-CD3/CD28 or P815 cells. Degranulation and cytotoxicity were assayed by flow cytometry (FCM). Expression of cytolytic molecules (granzymeB, perforin and IFN-g) and the transcription factors Eomes, T-bet and EZH2 were measured by FCM and qPCR. NAD production and protein acetylation were measured using colorimetric or Western blot techniques.

Results:

Compared with CD38low, CD38highCD8 T cells displayed lower cytotoxicity as determined by the expression of CD107a, granzymeB, perforin and IFNg. In addition, CD38highCD8 T cells showed lower cytotoxicity against P815 cells. Eomes and T-bet, which regulate cytotoxic function of CD8 T cells, were decreased in CD38highCD8 T cells, while EZH2 levels were increased. EZH2 known to repress Eomes and T-bet has been reported to have a higher suppressive capacity and stability when acetylated. SIRT1 is a NAD-dependent deacetylase and controls EZH2 acetylation. Consequent upon lower production of NAD, the levels of proteins acetylated on lysine residues increased in CD38highCD8 T cells. Lower deacetylation activity of SIRT1 may cause higher acetylation of EZH2 and suppression of Eomes and T-bet in CD38highCD8 T cells. Finally, overexpression of CD38 in CD38lowCD8 T cells or TALL-104 cells increased acetylated protein and decreased degranulation and cytotoxicity against P815 cells, which indicates that CD38 may reprogram cytotoxicity in CD8 T cells.

Normal: CD38↓→NAD↑→SIRT1 activity (deacetylase)↑→EZH2↓

→Eomes, T-bet↑→Cytotoxicity↑

SLE: CD38↑→NAD↓→SIRT1 activity (deacetylase)↓→EZH2↑

→Eomes, T-bet↓→Cytotoxicity↓

Conclusion: We present novel evidence that CD38highCD8 T cells which are expanded in patients with SLE display decreased cytotoxicity. CD38 causes decreased NAD levels, higher acetylation of EZH2 and subsequent decrease of the cytotoxicity-linked transcription factors, Eomes and T-bet. Our data document the role of CD38 in the control of the cytotoxic response of CD8 T cells and provide a molecular explanation for the known decreased cytotoxic responses in patients with SLE.


Disclosure: E. Katsuyama, None; A. Suarez-Fueyo, None; S. Bradley, None; M. Kono, None; L. Mulki, None; V. C. Kyttaris, None; G. C. Tsokos, None.

To cite this abstract in AMA style:

Katsuyama E, Suarez-Fueyo A, Bradley S, Kono M, Mulki L, Kyttaris VC, Tsokos GC. High Level of CD38 Expression in SLE CD8 T Cells Dictates Decreased Cytotoxicity [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/high-level-of-cd38-expression-in-sle-cd8-t-cells-dictates-decreased-cytotoxicity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-level-of-cd38-expression-in-sle-cd8-t-cells-dictates-decreased-cytotoxicity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology